Drug-Eluting Balloon Catheters Market SWOT Analysis of Top Key Player & Forecasts To 2028 The Drug-Eluting Balloon Catheters Market study focuses major leading industry players with information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. It provides information on trends and developments, and focuses on markets and materials, capacities and technologies, and on the changing structure. Browse key industry insights spread across 165 pages with 221 market data tables & 14 figures & charts from the report, “Drug-Eluting Balloon Catheters Market Analysis By Product (Coronary Artery Disease Drug Eluting Balloon Catheters {Paclitaxel, Sirolimus}, Peripheral Vascular Disease Drug Eluting Balloon Catheters {Paclitaxel, Sirolimus}), By Enduse (Hospitals and Clinics, Ambulatory Surgical Centers, Catheterization Laboratories), Industry Analysis Report, Regional Outlook , Growth Potential, Competitive Market Share & Forecast, 2022– 2028” in detail along with the table of contents: https://www.gminsights.com/industry-analysis/drug-eluting-balloon-catheters-market Recently, key industry players have been focusing on the development of economical and precise drug-eluting balloon catheters that are effective in improving medication delivery, which has fostered drug-eluting balloon catheters market growth significantly. For instance, in August 2019, B. Braun, an expert in interventional procedures and a part of B. Braun Group of Companies, received the U.S. Food and Drug Administration's breakthrough device designation for its SeQuent Please ReX drug-coated PTCA balloon stent in treating coronary in-stent restenosis (ISR). Similarly, in November 2021, Biosensors International Group Ltd., a medical devices firm, that its Biolimus drug-coated balloon catheters showed effective experimental results in small coronary vessels tested during the BIO-RISE CHINA study. It has been proclaimed as a new therapeutic option for the treatment of small vessel coronary artery disease for patients undergoing PCI. Notably, the COVID-19 pandemic has imposed a huge threat to people's health worldwide, particularly affecting those with underlying heart diseases. This has led to an unprecedented surge in treatment innovations to find efficient solutions to the viral infection, which has positively impacted the product scenario. To that effect, in April 2022, Medtronic, a leading medical devices firm, announced that its Symplicity Spyral RDN (renal denervation) system showed clinically significant and durable blood pressure reductions over three years in patients who were prescribed medication. The drug-eluting balloon catheters sector has been divided based on end-use, product, and region. In terms of product, the industry has been further segregated into peripheral vascular disease & coronary artery disease drug-eluting balloon catheters.
© 2022 Global Market Insights Inc. All Rights Reserved
www.gminsights.com